海南医学院学报2017，Vol.23Issue(4)：510-513,4.DOI:10.13210/j.cnki.jhmu.20161216.005
DC-CIK 细胞联合化疗对晚期非小细胞肺癌患者免疫功能的影响
Effect of DC-CIK in combined with chemotherapy on the immunological function in patients with advanced non-small cell lung cancer
摘要
Abstract
[ABSTRACT]Objective:To explore the effect of DC-CIK in combined with chemotherapy on the immunological function in patients with advanced non-small cell lung cancer (NSCLC).Methods:A total of 86 patients with NSCLC who were admitted in our hospital were included in the study and randomized into the observation group and the control group with 43 cases in each group.The patients in the two groups were given routine chemotherapy.On this basis,the patients in the observation group were given DC-CIK cellular immunotherapy.The patients in the two groups were treated for 3 courses.The peripheral blood T lymphocytes and cytokines after treatment in the two groups were compared.The clinical efficacy and adverse reactions in the two groups were evaluated.Results:The total effective rate and disease control rate after treatment in the observation group were slightly higher than those in the control group,but the comparison between the two groups was not statistically signifi-cant (P >0.05).CD8 + after treatment in the observation group was significantly reduced,while CD3 + ,CD4 + ,and CD4 +/CD8 + were significantly elevated when compared with before treatment (P <0.05).CD3 + and NK contents,and CD4 +/CD8 +after treatment in the observation group were significantly higher than those in the control group (P <0.05 ).IFN-γ,IL-4, TNF-αlevels,and Th1/Th2 after treatment in the observation group were significantly higher than those in the control group (P <0.05),while TGF-βlevel was significantly lower than that in the control group (P <0.05).The occurrence rate of nausea and vomiting,and liver and renal function damage in the observation group was significantly lower than that in the control group (P <0.05),but the median progression free survival (PFS)was significantly longer than that in the control group (P <0.05),while the comparison of median overall survival (OS)between the two groups was not statistically significant (P >0. 05),and 2-year survival rate was significantly higher than that in the control group (P <0.05).Conclusions:DC-CIK in com-bined with chemotherapy can correct the immunologic disorder in patients with advanced NSCLC,and strengthen the anti-tumor effect.关键词
非小细胞肺癌/DC-CIK 细胞免疫治疗/淋巴细胞/免疫功能Key words
NSCLC/DC-CIK cellular immunotherapy/Lymphocyte/Immunological function分类
医药卫生引用本文复制引用
周世繁..DC-CIK 细胞联合化疗对晚期非小细胞肺癌患者免疫功能的影响[J].海南医学院学报,2017,23(4):510-513,4.基金项目
河南中医学院苗圃工程自然科学研究项目(MP2011-22)[Foundation Project]:The study was supported by the Natural Science Research Project of Nursery Engineering of Henan Traditional Chinese Medicine with the number of MP 2011-22． （MP2011-22）
